Lantern Pharma Inc

Lantern Pharma has established Open Medicine AI as a separate company with commercial licenses and agreements in place, a move CEO Panna Sharma called the most consequential structural decision since starting Lantern. The company reported a net loss of approximately $7.1 million, or $0.57 per share, for the second quarter of 2026, with R&D expenses of about $1.8 million and G&A expenses of about $1.7 million. Management highlighted a subgroup signal for LP-300 in never-smokers with non-small cell lung cancer after TKI therapy, where L858R patients who completed six cycles had a median progression-free survival of 8.9 months and a hazard ratio of 0.37. For LP-184, the company received clearance in July for an investigator-initiated Phase Ib/II trial in advanced bladder cancer, and an FDA-cleared protocol is moving toward launch for a monotherapy trial in relapsed/refractory triple-negative breast cancer. Cash, cash equivalents, and marketable securities were approximately $7.4 million at June 30, 2026, and management said additional funding is a top priority to extend the operating runway.